Magentiq Eye

Improving Colonoscopy through AI

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in August 2014 by Dror Zur, Magentiq Eye operates with 11–50 employees. The company has raised $6.1M across 9 funding rounds from 8 investors. In July 2025, Magentiq Eye secured Series A funding from investors including aMoon Fund.

Business overview

Magentiq Eye develops an AI-aided colonoscopy solution, leveraging deep learning, image processing, and video processing technologies. Its core product, MAGENTIQ-COLO, is a real-time adjunct to colonoscopy devices designed to increase adenoma (polyp) detection rates and improve the overall quality of colonoscopy exams. The company serves the healthcare industry, specifically gastroenterology, by providing digital healthcare and medical decision support tools to medical providers in markets including the United States, Europe, and Japan.

Strategic signal

In February 2024, Magentiq Eye's AI-aided colonoscopy tool was highlighted for its ability to increase adenoma detection by 7%. This signifies a strong clinical validation and market acceptance of their technology, indicating a positive trajectory for product adoption and impact on patient outcomes in the medical device sector.

Company Intelligence Q&A

What is MAGENTIQ-COLO?
MAGENTIQ-COLO is Magentiq Eye's AI-aided colonoscopy solution that uses deep learning, image processing, and video processing to assist doctors in real-time during colonoscopy exams, aiming to improve adenoma (polyp) detection rates.
When did Magentiq Eye receive Series A funding?
In July 2025, Magentiq Eye received Series A funding from investors including aMoon Fund.
Has MAGENTIQ-COLO received regulatory clearances?
Yes, MAGENTIQ-COLO has received CE mark and FDA authorization for marketing as a cutting-edge AI gastrointestinal lesion software detection system, as announced in July 2023.
What was the impact of Magentiq Eye's AI tool on adenoma detection?
In February 2024, it was reported that Magentiq Eye's AI-aided colonoscopy tool increases adenoma detection by 7%, demonstrating its effectiveness in improving diagnostic accuracy.
Which investor participated in Magentiq Eye's SAFE funding round?
In December 2023, Magentiq Eye secured SAFE funding with participation from.

External links